US gets first COVID-19 vaccine for adolescents as Pfizer-BioNTech’s shot wins emergency approval


  • Pfizer - BioNTech’s COVID-19 vaccine has obtained the Emergency Use Authorization (EUA) in the US for adolescents.
  • The two companies also notified they had submitted data to the European Medicines Agency (EMA) and other worldwide regulators.
  • The pandemic continues to create havoc with the World Health Organization (WHO) reclassifying the triple mutant COVID-19 variant, emerging in India, as a variant of concern.

COVID-19 vaccine developed by Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) has been granted emergency approval from the Food and Drug Administration (FDA) for the children in the age group 12-15 in the US.

Earlier, the Centers for Disease Control and Prevention (CDC) highlighted that vaccination of children is crucial to achieving herd immunity and protecting the world against the virus. With the increasing spread of the highly contagious strain of novel coronavirus, having a vaccine for adolescents is considered a critical step to reduce the massive chaos caused by the COVID-19.  

DO READ: Experts believe vaccinating children is key to achieving herd immunity

Meanwhile, the World Health Organization (WHO) revealed that the agency is reclassifying the highly infectious triple mutant COVID-19 strain spreading in India as a variant of concern for the globe.

DID YOU KNOW: Experts warn of more COVID-19 variants as India reels under the deadly second wave

Pfizer’s COVID-19 vaccine gains emergency approval for Adolescents

Pfizer and BioNTech have announced that the US FDA has given the EUA (Emergency Use Authorization) to their vaccine for administration in adolescents. This is the first COVID-19 vaccine authorized in the country for individuals in the 12 - 15 years age bracket.

Source: © Info152 |

The FDA has concluded that the vaccine developed by Pfizer-BioNTech has met the statutory benchmarks to amend the EUA.

Notably, the vaccine has demonstrated 100% efficacy and was well-tolerated in Phase 3 clinical trials when tested in adolescents.

The partners have also submitted data to the EMA (European Medicines Agency) and other regulators worldwide. Further approvals are anticipated in the upcoming weeks.

Albert Bourla, Chairman and CEO of Pfizer, commented-

Furthermore, the pediatric clinical trial is evaluating the safety and efficacy of the vaccine in younger children aged six months to 11 years.

The FDA also stated that from 1 March 2020 through 30 April 2021, ~1.5 million COVID-19 cases were reported to the CDC in individuals aged 11 to 17 years.

The WHO reclassifies triple mutant COVID variant

The WHO disclosed that it is reclassifying the triple mutant variant of the novel coronavirus that is creating havoc in India as a variant of concern. The technical lead of WHO for COVID-19, Maria Van Kerkhove, stated that in primary studies B.1.617 variant had been discovered to circulate more rapidly than the original coronavirus. Besides, there is some evidence that the new variant might evade the protections provided by the available COVID-19 vaccines.

Source: Copyright © 2020 Kalkine Media

As per the WHO, a variant can be categorized as a variant of concern if proven to be more deadly, more transmissible, or more resistant to the available COVID-19 vaccines and treatments.

DO READ: Experts warn of more COVID-19 variants as India reels under the deadly second wave

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK